Get the Stockscreener App
33.60
3.13%
0.99
Avidity Biosciences Inc stock is traded at $33.60, with a volume of 741.15K.
It is up +3.13% in the last 24 hours and up +1.85% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$32.61
Open:
$34.4
24h Volume:
741.15K
Relative Volume:
0.58
Market Cap:
$4.13B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-11.63
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
+10.81%
1M Performance:
+1.85%
6M Performance:
-19.37%
1Y Performance:
+35.44%
1-Day Range:
$33.19
$36.38
1-Week Range:
$28.92
$36.38
52-Week Range:
$21.56
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
33.62 | 4.13B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.27 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.83 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.21 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.31 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.51 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences Stock Climbs Amid Promising Prospects - TipRanks
BMO Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform Recommendation - MSN
Avidity Biosciences chief scientific officer sells $602,614 in stock - Investing.com
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PR Newswire
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Benzinga India
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Avidity Biosciences to Participate in Upcoming Investor Conferen - GuruFocus.com
BMO starts coverage on Avidity with 'outperform', says first-in-disease therapies in sight - TradingView
BMO Capital Initiates Avidity Biosciences at Outperform With $72 Price Target -March 12, 2025 at 07:10 am EDT - Marketscreener.com
Avidity Biosciences’s SWOT analysis: RNA therapy pioneer’s stock poised for growth - Investing.com India
Avidity Biosciences (NASDAQ:RNA) Price Target Cut to $48.00 by Analysts at Bank of America - Defense World
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Contrasting Teva Pharmaceutical Industries (NYSE:TEVA) and Avidity Biosciences (NASDAQ:RNA) - Defense World
Scotiabank Initiates Coverage on Avidity Biosciences (NASDAQ:RNA) - Defense World
Scotiabank Initiates Coverage of Avidity Biosciences (RNA) with Sector Outperform Recommendation - Nasdaq
Principal Financial Group Inc. Has $275,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Scotiabank starts Avidity Biosciences with bullish $70 target - Investing.com India
Avidity Biosciences initiated with an Outperform at Scotiabank - TipRanks
Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights - GuruFocus.com
Avidity Biosciences chief program officer sells $172,807 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief program officer sells $172,807 in stock - Investing.com India
13,281 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Y Intercept Hong Kong Ltd - Defense World
Avidity Biosciences (NASDAQ:RNA) Shares Gap Down on Analyst Downgrade - Defense World
Avidity Biosciences’ (RNA) “Buy” Rating Reiterated at Chardan Capital - Defense World
Barclays Has Lowered Expectations for Avidity Biosciences (NASDAQ:RNA) Stock Price - Defense World
Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Chardan Capital - MarketBeat
Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance UK
Barclays Cuts Avidity Biosciences (NASDAQ:RNA) Price Target to $57.00 - MarketBeat
Handelsbanken Fonder AB Invests $788,000 in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Honors Rare Disease Day® and Global Efforts - GuruFocus.com
Avidity Biosciences Advances RNA Therapeutics for Rare Diseases - TipRanks
Avidity Biosciences (NASDAQ:RNA) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Positive Outlook for Avidity Biosciences Driven by Promising Pipeline Developments and Strong Financial Position - TipRanks
Avidity Biosciences: Promising Drug Pipeline and Potential Approval for DMD44 Drive Buy Rating - TipRanks
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases – Company AnnouncementFT.com - Financial Times
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com UK
Avidity Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
RBC Cuts Price Target on Avidity Biosciences to $61 From $67, Keeps Outperform, Speculative Risk - Marketscreener.com
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Rhumbline Advisers Purchases 4,795 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences: Promising Clinical Developments and Strong Financial Position Justify Buy Rating - TipRanks
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Avidity Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Avidity Biosciences, Inc. SEC 10-K Report - TradingView
Avidity Biosciences reports Q4 EPS (80c), consensus (78c) - TipRanks
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights - PR Newswire
State of New Jersey Common Pension Fund D Increases Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences to Participate in Upcoming Investor Conferences - BioSpace
Avidity Biosciences to Participate in Upcoming Investor Conferences – Company Announcement - Financial Times
Biotech Spotlight: How Avidity Biosciences Plans to Engage Investors Across Three Key March Conferences - StockTitan
Avidity Biosciences: Looks Tempting, But Wait For Interim Phase 3 Data (NASDAQ:RNA) - Seeking Alpha
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Flanagan W. Michael | Chief Scientific Officer |
Mar 11 '25 |
Sale |
30.13 |
20,000 |
602,614 |
91,975 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):